<code id='5431CD3F76'></code><style id='5431CD3F76'></style>
    • <acronym id='5431CD3F76'></acronym>
      <center id='5431CD3F76'><center id='5431CD3F76'><tfoot id='5431CD3F76'></tfoot></center><abbr id='5431CD3F76'><dir id='5431CD3F76'><tfoot id='5431CD3F76'></tfoot><noframes id='5431CD3F76'>

    • <optgroup id='5431CD3F76'><strike id='5431CD3F76'><sup id='5431CD3F76'></sup></strike><code id='5431CD3F76'></code></optgroup>
        1. <b id='5431CD3F76'><label id='5431CD3F76'><select id='5431CD3F76'><dt id='5431CD3F76'><span id='5431CD3F76'></span></dt></select></label></b><u id='5431CD3F76'></u>
          <i id='5431CD3F76'><strike id='5431CD3F76'><tt id='5431CD3F76'><pre id='5431CD3F76'></pre></tt></strike></i>

          
          WSS
          Jeremey Wyatt ActiGraph

          As drugmakers wade into using digital health technologies, ActiGraph has made its mission to become the wearable of choice for the industry.

          The Pensacola, Fla.-based company creates  devices and software explicitly designed for clinical trials by focusing on features that matter to sponsors, like bulletproof reliability, access to raw sensor data, and 30-day battery life so that trial participants never have to worry about charging devices.

          advertisement

          There are many potential advantages to using wearables in clinical trials. Continuous data may collect a more comprehensive picture of how a patient responds to treatment and could help drugmakers complete trials faster with fewer participants. But risk-averse companies have been slow to adopt the technology and opt instead for the certainty of established methods for capturing data. The industry has yet to see a drug approved with evidence from a wearable device.

          Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

          GET STARTED Log In

          Leave your comment

          Please enter your name
          Please enter your comment

          fashion